Long-term data from the phase 3 ALPINE trial continue to support the use of zanubrutinib (Brukinsa) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The final comparative analysis of the ALPINE trial highlights the efficacy and safety profile of zanubrutinib, reinforcing its role in the treatment landscape.
ALPINE Trial Key Findings
The ALPINE trial (NCT03734016) is a phase 3 study comparing zanubrutinib to ibrutinib in patients with relapsed/refractory CLL. Nicole Lamanna, MD, an associate clinical professor of medicine at Columbia University, discussed key efficacy data from the trial with Alexey Danilov, MD, PhD, of City of Hope. The discussion, hosted by OncLive On Air ®, covered zanubrutinib-associated toxicities and the future of BTK inhibitor-based therapy in CLL.
Expert Perspectives on Zanubrutinib in CLL
Drs. Danilov and Lamanna shared insights on the clinical implications of the ALPINE trial data. They addressed how zanubrutinib fits into the current treatment paradigm for CLL and strategies for managing potential side effects associated with the drug. The experts also explored the evolving role of BTK inhibitors and future directions for CLL therapy.
Managing Zanubrutinib-Associated Toxicities
While zanubrutinib has demonstrated a favorable safety profile compared to some other BTK inhibitors, it is important to be aware of potential toxicities. The discussion included practical guidance on monitoring and managing these side effects to optimize patient outcomes.
